



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Eberhardt HILDT *et al.*)
Application No.: 09/830,981) Examiner: Myron G. Hill
Filed: October 29, 2001) Group Art Unit: 1648
For: POLYPEPTIDE MEDIATING CELL) Docket No. VOS-202
PERMEABILITY)

STATEMENT UNDER 37 CFR 1.821(f)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

I hereby state that, to the best of my information and belief, the sequence listing information submitted herewith, recorded in computer readable form, is identical to the paper copy of the Sequence Listing, submitted in accordance with 37 CFR 1.821 (c) and (e).

Respectfully submitted,

Dated: March 16, 2004

OLSON & HIERL, LTD.
20 North Wacker Drive
36th floor
Chicago, Illinois 60606
(312) 580-1180

By: Dolores T. Kenney
Dolores T. Kenney (Reg. No. 31,269)



- 1 -

SEQUENCE LISTING

<110> Hildt, Eberhard
Schmidt, Stephanie

<120> Polypeptide Mediating Cell Permeability

<130> VOS-202

<140> US 09/830,981

<141> 2001-10-29

<150> PCT/DE99/03506

<151> 1999-11-03

<150> DE 198 50 718.6

<151> 1998-11-03

<160> 13

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 36

<212> DNA

<213> Hepadnavirus

<220>

<221> CDS

<222> (1) ... (36)

<400> 1

ccc tta tcg tca atc ttc tcg agg att ggg gac cct
Pro Leu Ser Ser Ile Phe Ser Arg Ile Gly Asp Pro
1 5 10

36

<210> 2

<211> 12

<212> PRT

<213> Hepadnavirus

<400> 2

Pro Leu Ser Ser Ile Phe Ser Arg Ile Gly Asp Pro
1 5 10

<210> 3

<211> 36

<212> DNA

<213> Hepadnavirus



- 2 -

<220>

<221> CDS

<222> (1)...(36)

<400> 3

ccc ata tcg tca atc ttc tcg agg att ggg gac cct
Pro Ile Ser Ser Ile Phe Ser Arg Ile Gly Asp Pro
1 5 10

36

<210> 4

<211> 12

<212> PRT

<213> Hepadnavirus

<400> 4

Pro Ile Ser Ser Ile Phe Ser Arg Ile Gly Asp Pro
1 5 10

<210> 5

<211> 36

<212> DNA

<213> Hepadnavirus

<220>

<221> CDS

<222> (1)...(36)

<400> 5

ccc ata tcg tca atc ttc tcg agg act ggg gac cct
Pro Ile Ser Ser Ile Phe Ser Arg Thr Gly Asp Pro
1 5 10

36

<210> 6

<211> 12

<212> PRT

<213> Hepadnavirus

<400> 6

Pro Ile Ser Ser Ile Phe Ser Arg Thr Gly Asp Pro
1 5 10

<210> 7

<211> 36

<212> DNA

<213> Hepadnavirus

<220>

<221> CDS

<222> (1)...(36)

<400> 7

cac atc tgc tca atc tcc gcg agg act ggg gac cct
His Ile Ser Ser Ile Ser Ala Arg Thr Gly Asp Pro
1 5 10

36

<210> 8

<211> 12

<212> PRT

<213> Hepadnavirus

<400> 8

His Ile Ser Ser Ile Ser Ala Arg Thr Gly Asp Pro
1 5 10

<210> 9

<211> 12

<212> PRT

<213> Hepadnavirus

<400> 9

Leu Leu Asn Gln Leu Ala Gly Arg Met Ile Pro Lys
1 5 10

<210> 10

<211> 12

<212> PRT

<213> Hepadnavirus

<400> 10

Thr Ile Asp His Val Leu Asp His Val Gln Thr Met
1 5 10

<210> 11

<211> 12

<212> PRT

<213> Hepadnavirus

<400> 11

Thr Ile Gln His Val Met Asp His Ile Asp Ser Val
1 5 10

<210> 12

<211> 12

<212> PRT

<213> Hepadnavirus

<400> 12

Thr Leu Ser Pro Val Val Pro Thr Val Ser Thr Ile
1 5 10

<210> 13

<211> 12

<212> PRT

<213> Hepadnavirus

<400> 13

Thr Leu Ser Pro Val Val Pro Thr Val Ser Thr Thr
1 5 10